Citations (49)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Sara De Santis, Cecilia Monaldi, Manuela Mancini, Samantha Bruno, Michele Cavo & Simona Soverini. (2022) Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia. OncoTargets and Therapy 15, pages 103-116.
Read now
Read now
Susan L. Heatley, Kartini Asari, Caitlin E. Schutz, Tamara M. Leclercq, Barbara J. McClure, Laura N. Eadie, Timothy P. Hughes, David T. Yeung & Deborah L. White. (2021) In-vitro modeling of TKI resistance in the high-risk B-cell acute lymphoblastic leukemia fusion gene RANBP2-ABL1 - implications for targeted therapy. Leukemia & Lymphoma 62:5, pages 1157-1166.
Read now
Read now
Wen-Jing Li, Xin-Hui Chen, Jia-Cheng Zeng, Li-Li Duan, Zhao-Hua Liu & Xie-Huang Sheng. (2020) Theoretical insight into the multiple interactions of quinazoline inhibitors with breast cancer resistance protein (BCRP/ABCG2). Journal of Biomolecular Structure and Dynamics 38:14, pages 4336-4343.
Read now
Read now
Stephany Corrêa, Renata Binato, Bárbara Du Rocher, Gerson Ferreira, Paola Cappelletti, Sheila Soares-Lima, Luis Felipe Pinto, André Mencalha & Eliana Abdelhay. (2014) ABCB1 regulation through LRPPRC is influenced by the methylation status of the GC -100 box in its promoter. Epigenetics 9:8, pages 1172-1183.
Read now
Read now
Laura N. Eadie, Verity A. Saunders, Timothy P. Hughes & Deborah L. White. (2013) Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2. Leukemia & Lymphoma 54:3, pages 569-578.
Read now
Read now
Maria Karvela, G Vignir Helgason & Tessa L Holyoake. (2012) Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Expert Review of Anticancer Therapy 12:3, pages 381-392.
Read now
Read now
Articles from other publishers (43)
H. Jonathan G. Lindström, Astrid S. de Wijn & Ran Friedman. (2023) Interplay of mutations, alternate mechanisms, and treatment breaks in leukaemia: Understanding and implications studied with stochastic models. Computers in Biology and Medicine, pages 107826.
Crossref
Crossref
Benjamin C. S. Leow, Chung H. Kok, David T. Yeung, Timothy P. Hughes, Deborah L. White & Laura N. Eadie. (2023) The acquisition order of leukemic drug resistance mutations is directed by the selective fitness associated with each resistance mechanism. Scientific Reports 13:1.
Crossref
Crossref
Martín Ledesma, Daniela Poodts, Sofía Amoia, Silvia Hajos, Ariela Fundia, Carlos Vay, Matías Pibuel & Silvina Lompardía. (2023) Discrimination of the chemotherapy resistance status of human leukemia and glioblastoma cell lines by MALDI-TOF-MS profiling. Scientific Reports 13:1.
Crossref
Crossref
Thao T. T. Nguyen, Minori Tamai, Daisuke Harama, Keiko Kagami, Shin Kasai, Atsushi Watanabe, Koshi Akahane, Kumiko Goi & Takeshi Inukai. (2022) Introduction of the T315I gatekeeper mutation of BCR/ABL1 into a Philadelphia chromosome-positive lymphoid leukemia cell line using the CRISPR/Cas9 system. International Journal of Hematology 116:4, pages 534-543.
Crossref
Crossref
Chung-Pu Wu, Megumi Murakami, Yu-Shan Wu, Chun-Ling Lin, Yan-Qing Li, Yang-Hui Huang, Tai-Ho Hung & Suresh V. Ambudkar. (2022) The multi-targeted tyrosine kinase inhibitor SKLB610 resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs. Biomedicine & Pharmacotherapy 149, pages 112922.
Crossref
Crossref
Noureldien H. E. Darwish, Gennadi V. Glinsky, Thangirala Sudha & Shaker A. Mousa. (2022) Targeting Thyrointegrin αvβ3 Using Fluorobenzyl Polyethylene Glycol Conjugated Tetraiodothyroacetic Acid (NP751) in Acute Myeloid Leukemia. Frontiers in Oncology 11.
Crossref
Crossref
Pranav Gupta, Yunali V. Ashar, Charles R. AshbyJr.Jr., Lusheng Lin & Zhe-Sheng Chen. 2022. Comprehensive Pharmacology. Comprehensive Pharmacology
312
328
.
Chung-Pu Wu, Megumi Murakami, Yu-Shan Wu, Ya-Chen Chi, Sung-Han Hsiao, Yang-Hui Huang, Tai-Ho Hung & Suresh V. Ambudkar. (2021) Branebrutinib (BMS-986195), a Bruton’s Tyrosine Kinase Inhibitor, Resensitizes P-Glycoprotein-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Agents. Frontiers in Cell and Developmental Biology 9.
Crossref
Crossref
H. Jonathan G. Lindström & Ran Friedman. (2020) Inferring time-dependent population growth rates in cell cultures undergoing adaptation. BMC Bioinformatics 21:1.
Crossref
Crossref
Chung-Pu Wu, Sabrina Lusvarghi, Sung-Han Hsiao, Te-Chun Liu, Yan-Qing Li, Yang-Hui Huang, Tai-Ho Hung & Suresh V. Ambudkar. (2020) Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs. Journal of Natural Products 83:5, pages 1461-1472.
Crossref
Crossref
Daniel Nisakar Meenakshi Sundaram, Xiaoyan Jiang, Joseph M. Brandwein, Juliana Valencia-Serna, K.C. Remant & Hasan Uludağ. (2019) Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options. Drug Discovery Today 24:7, pages 1355-1369.
Crossref
Crossref
Ramachandran Krishna Chandran, Narayanan Geetha, Kunnathur Murugesan Sakthivel, Raveendran Suresh Kumar, Kumarapillai Mohanan Nair Jagathnath Krishna & Hariharan Sreedharan. (2019) Differential gene expression changes and their implication on the disease progression in patients with Chronic Myeloid Leukemia. Blood Cells, Molecules, and Diseases 77, pages 51-60.
Crossref
Crossref
Chung-Pu Wu & Sheng-Chieh Hsu. 2019. Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy. Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy
169
185
.
Kamal SweidanHiba ZalloumDima A. SabbahGhada IdrisKhadija AbudoshMohammad S. Mubarak. (2018)
Synthesis, characterization, and anticancer evaluation of some new
N
1-(anthraquinon-2-yl) amidrazone derivatives
. Canadian Journal of Chemistry 96:12, pages 1123-1128.
Crossref
Crossref
Chen Huan, Lou Jin, Wang Heng, An Na, Pan Yuming, Du Xin & Zhang Qiaoxia. (2018) MXD1 regulates the imatinib resistance of chronic myeloid leukemia cells by repressing BCR-ABL1 expression. Leukemia Research 75, pages 1-6.
Crossref
Crossref
Liu Lu, Chung Hoow Kok, Verity Ann Saunders, Jueqiong Wang, Jennifer Anne McLean, Timothy Peter Hughes & Deborah Lee White. (2018)
Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant
BCR-ABL1
+ cell lines
. Oncotarget 9:78, pages 34735-34747.
Crossref
Crossref
Sung-Han Hsiao, Megumi Murakami, Ni Yeh, Yan-Qing Li, Tai-Ho Hung, Yu-Shan Wu, Suresh V. Ambudkar & Chung-Pu Wu. (2018) The positive inotropic agent DPI-201106 selectively reverses ABCB1-mediated multidrug resistance in cancer cell lines. Cancer Letters 434, pages 81-90.
Crossref
Crossref
Laura N. Eadie, Verity A. Saunders, Susan Branford, Deborah L. White & Timothy P. Hughes. (2018)
The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression
in vitro
. Oncotarget 9:17, pages 13423-13437.
Crossref
Crossref
Laura N. Eadie, Phuong Dang, Jarrad M. Goyne, Timothy P. Hughes & Deborah L. White. (2018) ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells. PLOS ONE 13:1, pages e0192180.
Crossref
Crossref
Federico Lussana, Tamara Intermesoli, Paola Stefanoni & Alessandro Rambaldi. 2018. Mechanisms of Drug Resistance in Cancer Therapy. Mechanisms of Drug Resistance in Cancer Therapy
231
250
.
Giovanni Luca Beretta, Giuliana Cassinelli, Marzia Pennati, Valentina Zuco & Laura Gatti. (2017) Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents. European Journal of Medicinal Chemistry 142, pages 271-289.
Crossref
Crossref
Érica Aparecida de Oliveira, Diogenes Saulo de Lima, Lucas Esteves Cardozo, Garcia Ferreira de Souza, Nayane de Souza, Debora Kristina Alves-Fernandes, Fernanda Faião-Flores, José Agustín Pablo Quincoces, Silvia Berlanga de Moraes Barros, Helder I. Nakaya, Gisele Monteiro & Silvya Stuchi Maria-Engler. (2017) Toxicogenomic and bioinformatics platforms to identify key molecular mechanisms of a curcumin-analogue DM-1 toxicity in melanoma cells. Pharmacological Research 125, pages 178-187.
Crossref
Crossref
Kelly Airiau, Béatrice Turcq, François-Xavier Mahon & Francis Belloc. (2017) A new mechanism of resistance to ABL1 tyrosine kinase inhibitors in a BCR-ABL1-positive cell line. Leukemia Research 61, pages 44-52.
Crossref
Crossref
Chung-Pu Wu, Sung-Han Hsiao, Megumi Murakami, Yu-Jen Lu, Yan-Qing Li, Yang-Hui Huang, Tai-Ho Hung, Suresh. V. Ambudkar & Yu-Shan Wu. (2017) Alpha-Mangostin Reverses Multidrug Resistance by Attenuating the Function of the Multidrug Resistance-Linked ABCG2 Transporter. Molecular Pharmaceutics 14:8, pages 2805-2814.
Crossref
Crossref
Chung-Pu Wu, Megumi Murakami, Sung-Han Hsiao, An-Wei Chou, Yan-Qing Li, Yang-Hui Huang, Tai-Ho Hung & Suresh. V. Ambudkar. (2017) Overexpression of ATP-Binding Cassette Subfamily G Member 2 Confers Resistance to Phosphatidylinositol 3-Kinase Inhibitor PF-4989216 in Cancer Cells. Molecular Pharmaceutics 14:7, pages 2368-2377.
Crossref
Crossref
Ana P Azevedo, Alice Reichert, Celina Afonso, Maria D Alberca, Purificação Tavares & Fernando Lima. (2017)
BCR-ABL
V280G Mutation, Potential Role in Imatinib Resistance: First Case Report
. Clinical Medicine Insights: Oncology 11, pages 117955491770287.
Crossref
Crossref
L N Eadie, P Dang, V A Saunders, D T Yeung, M P Osborn, A P Grigg, T P Hughes & D L White. (2016) The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment. Leukemia 31:1, pages 75-82.
Crossref
Crossref
Steven B. Ouellette, Brett M. Noel & Laurie L. Parker. (2016) A Cell-Based Assay for Measuring Endogenous BcrAbl Kinase Activity and Inhibitor Resistance. PLOS ONE 11:9, pages e0161748.
Crossref
Crossref
Laura N. Eadie, Timothy P. Hughes & Deborah L. White. (2016) ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell Lines. PLOS ONE 11:8, pages e0161470.
Crossref
Crossref
Chung-Pu Wu, Ya-Ju Hsieh, Sung-Han Hsiao, Ching-Ya Su, Yan-Qing Li, Yang-Hui Huang, Chiun-Wei Huang, Chia-Hung Hsieh, Jau-Song Yu & Yu-Shan Wu. (2016) Human ATP-Binding Cassette Transporter ABCG2 Confers Resistance to CUDC-907, a Dual Inhibitor of Histone Deacetylase and Phosphatidylinositol 3-Kinase. Molecular Pharmaceutics 13:3, pages 784-794.
Crossref
Crossref
L Lu, V A Saunders, T M Leclercq, T P Hughes & D L White. (2015) Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells. Leukemia 29:8, pages 1792-1794.
Crossref
Crossref
Ke Yang & Li-wu Fu. (2015) Mechanisms of resistance to BCR–ABL TKIs and the therapeutic strategies: A review. Critical Reviews in Oncology/Hematology 93:3, pages 277-292.
Crossref
Crossref
Martin Michaelis, Florian Rothweiler, Thomas Nerreter, Marijke van Rikxoort, Richard Zehner, Wilhelm G Dirks, Michael Wiese & Jindrich CinatlJrJr. (2014) Association between acquired resistance to PLX4032 (vemurafenib) and ATP-binding cassette transporter expression. BMC Research Notes 7:1.
Crossref
Crossref
Chung-Pu Wu, Sung-Han Hsiao, Ching-Ya Su, Shi-Yu Luo, Yan-Qing Li, Yang-Hui Huang, Chia-Hung Hsieh & Chiun-Wei Huang. (2014) Human ATP-Binding Cassette transporters ABCB1 and ABCG2 confer resistance to CUDC-101, a multi-acting inhibitor of histone deacetylase, epidermal growth factor receptor and human epidermal growth factor receptor 2. Biochemical Pharmacology 92:4, pages 567-576.
Crossref
Crossref
L N Eadie, T P Hughes & D L White. (2013) Interaction of the Efflux Transporters ABCB1 and ABCG2 With Imatinib, Nilotinib, and Dasatinib. Clinical Pharmacology & Therapeutics 95:3, pages 294-306.
Crossref
Crossref
Namrata Rastogi, Rishi Kumar Gara, Rachana Trivedi, Akanksha Singh, Preety Dixit, Rakesh Maurya, Shivali Duggal, M.L.B. Bhatt, Sarika Singh & Durga Prasad Mishra. (2014) (6)-Gingerolinduced myeloid leukemia cell death is initiated by reactive oxygen species and activation of miR-27b expression. Free Radical Biology and Medicine 68, pages 288-301.
Crossref
Crossref
Markus D. Herrmann, Jochen K. Lennerz, Lars Bullinger, Stephan Bartholomae, Karlheinz Holzmann, Mike-Andrew Westhoff, Selim Corbacioglu & Klaus-Michael Debatin. (2014) Transitory dasatinib-resistant states in KITmut t(8;21) acute myeloid leukemia cells correlate with altered KIT expression. Experimental Hematology 42:2, pages 90-100.
Crossref
Crossref
Angelica Martínez-Hernández, Humberto Gutierrez-Malacatt, Karol Carrillo-Sánchez, Yolanda Saldaña-Alvarez, Alberto Rojas-Ochoa, Erick Crespo-Solis, Alvaro Aguayo-González, Adriana Rosas-López, Jose Manuel Ayala-Sanchez, Xochitl Aquino-Ortega, Lorena Orozco & Emilio J Cordova. (2014)
Small MAF
genes variants and chronic myeloid leukemia
. European Journal of Haematology 92:1, pages 35-41.
Crossref
Crossref
Timothy P Hughes, David M Ross & Junia V MeloTimothy P. Hughes, David M. Ross & Junia V. Melo. 2014. Handbook of Chronic Myeloid Leukemia. Handbook of Chronic Myeloid Leukemia
53
65
.
Elias J. Jabbour, Jorge E. Cortes & Hagop M. Kantarjian. (2013) Resistance to Tyrosine Kinase Inhibition Therapy for Chronic Myelogenous Leukemia: A Clinical Perspective and Emerging Treatment Options. Clinical Lymphoma Myeloma and Leukemia 13:5, pages 515-529.
Crossref
Crossref
Ajit Bisen & David F. Claxton. 2013. Impact of Genetic Targets on Cancer Therapy. Impact of Genetic Targets on Cancer Therapy
179
196
.
Stephany Corrêa, Renata Binato, Bárbara Du Rocher, Morgana TL Castelo-Branco, Luciana Pizzatti & Eliana Abdelhay. (2012) Wnt/β-catenin pathway regulates ABCB1 transcription in chronic myeloid leukemia. BMC Cancer 12:1.
Crossref
Crossref
Eduardo Cervera, Myrna Candelaria, Omar L?pez-Navarro, Juan Labardini, Aurora Gonzalez-Fierro, Lucia Taja-Chayeb, Jorge Cortes, Daniela Gordillo-Bastidas & Alfonso Due?as-Gonz?lez. (2012) Epigenetic Therapy With Hydralazine and Magnesium Valproate Reverses Imatinib Resistance in Patients With Chronic Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia 12:3, pages 207-212.
Crossref
Crossref